Análise opcional do produto
Com a sua autorização, usamos análises limitadas e respeitadoras da privacidade para perceber que percursos de investigação funcionam. Não usamos rastreadores publicitários nem gravação de sessões. Pode alterar esta escolha nas Preferências. Leia a Política de Privacidade.
Centene Corporation's published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $31.1B |
|---|
| Revenue (ttm) | 180.4B |
|---|
| Net income (ttm) | 1.5B |
|---|
| EPS (ttm) | $2.95 |
|---|
| Shares out | 495.1M |
|---|
| P/E (trailing) | 22.7x |
|---|
| P/E (forward) | 11.2x |
|---|
| Volume | 4,954,935 |
|---|
| Beta | 1.13 |
|---|
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $117.98B | $135.48B | $140.10B | $145.51B | $174.58B | +10.3% |
| Gross profit | $14.49B | $16.92B | $17.64B | $17.07B | $14.21B | -0.5% |
| Operating income | $1.78B | $1.32B | $2.93B | $3.18B | $-7.62B | — |
| Net income | $1.35B | $1.20B | $2.70B | $3.31B | $-6.67B | — |
| EPS (diluted) | $2.28 | $2.07 | $4.95 | $6.31 | $-13.53 | — |
| EBITDA | $3.81B | $4.06B | $2.93B | $6.20B | $-5.14B | — |
| R&D | — | — | — | — | — | — |
| SG&A | $9.60B | $11.59B | $12.56B | $12.40B | $12.90B | +7.7% |
Recent company headlines from major financial publishers.
The base scenario represents the modal operating path with a target of $51.46 and an assigned probability of 55.0%, implying an expected return of -18.3% relative to $62.99. In this scenario, Centene successfully stabilizes its core Medicaid business as post-redetermination member attrition concludes and state actuarial rate adjustments gradually align with medical cost trends. Commercial Marketplace operations deliver pretax margins within the guided range, supported by positive risk-adjustment transfers. Overhead streamlining initiatives lower administrative expense ratios, supporting normalized operating margins and driving diluted earnings per share toward consensus expectations over the forecast horizon. Investors would confirm this path through consecutive quarters of stable medical loss ratios and realized administrative cost efficiencies.
The bull scenario outlines an accelerated recovery path toward Potential value of $59.33, reflecting a target of $59.33 and a probability of 20.0%, delivering a potential return of -5.8% from $62.99. This outcome requires state Medicaid rate increases to exceed medical inflation, fully restoring underwriting profitability across the core portfolio. Concurrently, favorable risk-adjustment determinations lift Commercial Marketplace margins beyond guided expectations, while enterprise overhead streamlining generates structural administrative cost reductions above initial targets. Robust cash conversion accelerates debt paydown, de-risking upcoming maturities and prompting market multiple expansion toward leading managed care peers. Disconfirmation would occur if state rate updates fail to exceed trend or exchange competition erodes pricing power.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 8.4% | $53.3 | $53.3 | $53.3 | $53.3 | $53.3 |
| 8.9% | $52.2 | $52.2 | $52.2 | $52.2 | $52.2 |
| 9.4% | $51.5 | $51.5 | $51.5 | $51.5 | $51.5 |
| 9.9% | $50.2 | $50.2 | $50.2 | $50.2 | $50.2 |
| 10.4% | $49.3 | $49.3 | $49.3 | $49.3 | $49.3 |
Upcoming earnings date and setup when available.
A classificação que a edição de pesquisa publicada em cada mês trazia. Uma classificação compara o preço na data da análise com o valor justo; não é um registro de se a avaliação se confirmou.
| Ano | jan. | fev. | mar. | abr. | mai. | jun. | jul. | ago. | set. | out. | nov. | dez. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
